Patent intelligence · US
US 6723716
7-acylamino-3-heteroarylthio-3-cephem carboxylic acid antibiotics and prodrugs thereof
7-acylamino-3-heteroarylthio-3-cephem carboxylic acid antibiotics and prodrugs thereof
Patent details — US 6723716
- Jurisdiction
- US
- Status
- expired
- Grant date
- Apr 20, 2004
- Expiration
- Apr 15, 2024
- Applicant
- Essential Therapeutics, Inc.
- Claims
- 23
- CPC classes
- A61P, A61P31/04
Quick answer
US 6723716 (7-acylamino-3-heteroarylthio-3-cephem carboxylic acid antibiotics and prodrugs thereof) is held by Essential Therapeutics, Inc.. Status: expired. Granted Apr 20, 2004. Expires Apr 15, 2024 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Essential Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 23
- CPC classes
- A61P, A61P31/04
More from Essential Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12419895
Methods for treating subjects with Prader-Willi syndrome
granted -
US 12350258
Compositions and methods for treatment of skin-related diseases and promoting dermatological health
granted -
US 12343348
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12343381
Dosage regimen for pegylated interferon
granted -
US 12178823
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12109216
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12005081
Chimeric receptors and methods of use thereof
granted -
US 11884656
Pyrrole derivatives as PLK1 inhibitors
granted
Frequently asked questions
What is US patent 6723716?
US 6723716 (7-acylamino-3-heteroarylthio-3-cephem carboxylic acid antibiotics and prodrugs thereof) is held by Essential Therapeutics, Inc.. Status: expired. Granted Apr 20, 2004. Expires Apr 15, 2024 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6723716?
Essential Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 95 pharmaceutical patents for this assignee.
When does US 6723716 expire?
Our index shows an expiration date of Apr 15, 2024 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.